Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Myeloid disease

Another action of a thalidomide derivative

Nature volume 523, pages 167–168 (2015)Cite this article

Subjects

Lenalidomide effectively treats a blood disorder caused by the 5q chromosomal deletion. A study shows that the drug binds to its target, CRBN, to promote the breakdown of an enzyme encoded by a gene in the 5q region. See Article p.183

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Thalidomide and its derivatives confer the substrate specificity of CRBN.

Notes

  1. See all news & views

References

  1. Ito, T., Ando, H. & Handa, H. Cell. Mol. Life Sci. 68, 1569–1579 (2011).

    Article  CAS  PubMed  Google Scholar 

  2. List, A. et al. N. Engl. J. Med. 355, 1456–1465 (2006).

    Article  CAS  PubMed  Google Scholar 

  3. Krönke, J. et al. Nature 523, 183–188 (2015).

    Article  ADS  PubMed  PubMed Central  Google Scholar 

  4. Ito, T. et al. Science 327, 1345–1350 (2010).

    Article  ADS  CAS  PubMed  Google Scholar 

  5. Fischer, E. S. et al. Nature 512, 49–53 (2014).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  6. Chamberlain, P. P. et al. Nature Struct. Mol. Biol. 21, 803–809 (2014).

    Article  CAS  Google Scholar 

  7. Krönke, J. et al. Science 343, 301–305 (2014).

    ADS  PubMed  Google Scholar 

  8. Lu, G. et al. Science 343, 305–309 (2013).

    Article  ADS  PubMed  PubMed Central  Google Scholar 

  9. Gandhi, A. K. et al. Br. J. Haematol. 164, 811–821 (2014)

    Article  CAS  PubMed  Google Scholar 

  10. Järås, M. et al. J. Exp. Med. 211, 605–612 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  11. Hartmann, M. D. et al. J. Struct. Biol. 188, 225–232 (2015).

    Article  Google Scholar 

  12. Tan, X. et al. Nature 446, 640–645 (2007).

    Article  ADS  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Takumi Ito and Hiroshi Handa are in the Department of Nanoparticle Translational Research, Tokyo Medical University, Shinjuku-ku, Tokyo, 160-8402, Japan.,

    Takumi Ito & Hiroshi Handa

Authors
  1. Takumi Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroshi Handa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroshi Handa.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ito, T., Handa, H. Another action of a thalidomide derivative. Nature 523, 167–168 (2015). https://doi.org/10.1038/nature14628

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nature14628

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer